SanBio (4592) · InitiativeRestated
Partnership with D&P Bioinnovations for the MSC2 Esophageal Regeneration Implant
First written in FY2022. 1 of 2 entries say "Restated". Latest entry: FY2023.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Joint development and commercialisation of an MSC2 esophageal regeneration implant with D&P BioinnovationsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「In November 2021, the Company also entered into a business partnership agreement with D&P Bioinnovations concerning the development and commercialization of an esophageal regeneration implant using MSC2 cells.」
The development and commercialisation alliance with D&P Bioinnovations for an oesophageal regenerative implant using MSC2 has been reconfirmed. - FY2022First statedAnnual report
「In November 2021, the Company also entered into a business partnership agreement with D&P Bioinnovations concerning the development and commercialization of an esophageal regeneration implant using MSC2 cells.」
The execution of a business alliance agreement with D&P Bioinnovations for the development and commercialisation of an oesophageal regenerative implant using MSC2 cells was reported for the first time.